Background: In Spring 2019, the University of California (UC) health system launched a UC Wide Diabetes Initiative. In response to the growing population of people with diabetes, as well as significant heterogeneity in diabetes care across five UC campuses, the UC Health Diabetes Initiative aims to increase alignment in methods of diabetes care delivery, and to improve clinical outcomes.

Methods: The UC Diabetes Initiative joins five financially and operationally independent academic medical campuses - UC Davis, UC San Francisco, UC Los Angeles, UC Irvine, and UC San Diego. Endocrinologists, primary care physicians, pharmacists, and program managers represent each campus, with data scientists and program leaders from the UC Office of the President. Powered by a central EHR data warehouse, we built a Diabetes Dashboard to show demographics, outcome (e.g., A1c) and process measures (e.g., eye exam) for more than 45,000 adults with diabetes cared for by more than 2,000 providers across the UC system.

Current Work: Our collaborative identified three focus domains for improvement: 1) Medical Neighborhood 2) Patient Education and 3) Pharmaceutical Use. Within each of these domains, we used a semi-structured approach based on local expertise and experience to narrow our focus. Specific interventions were selected based on potential impact, feasibility, and key stakeholder feedback. We focus on designing and delivering three UC-wide interventions to 1) increase use of A1c point-of-care testing 2) increase reach of diabetes education and 3) utilize a “UC-way” diabetes pharmaceutical algorithm. Implementation will begin in Summer 2020; our ongoing work will be the focus of subsequent evaluation.

Conclusions: The UC Health Diabetes Initiative provides a unique model of multi-institution collaboration joining independent health systems around a common mission, and using population-based real-world data to select, implement and measure best practices in diabetes care delivery.


T. Kompala: None. M. Clark: None. S. Kim: None. L. Kroon: None. T.A. Peterson: None. R.M. Mowers: None. P. Surampudi: None. M. Freeby: Research Support; Self; Abbott, Novo Nordisk Inc. M. Han: None. S. Lambrechts: None. T.M. Offer: None. M. Christian: None. L. Dahm: None. L. Gibbs: None. J. Bouw: None. K. Medders: Advisory Panel; Self; Lilly Diabetes. C. Morn: None. A. Patel: None. R. Sak: None. M. Cabrera: None. A.B. Neinstein: Consultant; Self; Steady Health.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at